Find Reports
Select Report Type
Reimbursement Review
Displaying 476 - 500 of 1426
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| risankizumab | Skyrizi | risankizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | SR0583-000 | |||
| cerliponase alfa | Brineura | cerliponase alfa | Neuronal Ceroid Lipofuscinosis Type 2 | Reimburse with clinical criteria and/or conditions | Complete | SR0574-000 | |||
| efinaconazole | Jublia | efinaconazole | Onychomycosis | Do not reimburse | Complete | SR0577-000 | |||
| Xalkori for ROS1-positive adva... | Xalkori | Crizotinib | ROS1-positive advanced non-small cell lung cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | PC0151-000 | |||
| semaglutide | Ozempic | semaglutide | Diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete | SR0594-000 | |||
| isavuconazole | Cresemba | isavuconazole | Treatment of invasive aspergillosis and mucormycosis | Reimburse with clinical criteria and/or conditions | Complete | SR0586-000 | |||
| doravirine lamuvidine tenofovi... | Delstrigo | doravirine lamuvidine tenofovir disoproxil fumarate | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | SR0581-000 | |||
| doravirine | Pifeltro | doravirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | SR0582-000 | |||
| Tafinlar & Mekinist in com... | Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete | PC0152-000 | |||
| Imfinzi for Non-Small Cell Lun... | Imfinzi | Durvalumab | Unresectable Non-Small Cell Lung Cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | PC0131-000 | |||
| Ibrance (with Faslodex) for Ad... | Ibrance (with Faslodex) | Palbociclib (with Fulvestrant) | Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0150-000 | |||
| Blincyto for Philadelphia Chro... | Blincyto | Blinatumomab | Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Complete | PC0146-000 | |||
| Folotyn for Peripheral T-Cell ... | Folotyn | Pralatrexate | Peripheral T-Cell Lymphoma (PTCL) | Reimburse with clinical criteria and/or conditions | Complete | PC0138-000 | |||
| reslizumab | Cinqair | reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | SF0591-000 | |||
| benralizumab | Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | SF0592-000 | |||
| mepolizumab | Nucala | mepolizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | SF0593-000 | |||
| crisaborole | Eucrisa | crisaborole | atopic dermatitis | Do not reimburse | Complete | SR0570-000 | |||
| edaravone | Radicava | edaravone | amyotrophic lateral sclerosis | Reimburse with clinical criteria and/or conditions | Complete | SR0573-000 | |||
| Xtandi for non-metastatic Cast... | Xtandi | Enzalutamide | Non-metastatic castration-resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Complete | PC0149-000 | |||
| Unituxin for Neuroblastoma – D... | Unituxin | Dinutuximab | Neuroblastoma | Reimburse with clinical criteria and/or conditions | Complete | PC0154-000 | |||
| Opdivo for Melanoma Adjuvant T... | Opdivo | Nivolumab | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete | PC0147-000 | |||
| Adcetris for Hodgkin Lymphoma ... | Adcetris (Resubmission) | Brentuximab Vedotin | Hodgkin lymphoma (HL) | Do not reimburse | Complete | PC0145-000 | |||
| tofacitinib | Xeljanz | tofacitinib | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | SR0572-000 | |||
| Nusinersen | Spinraza | Nusinersen | Spinal Muscular Atrophy | Reimburse with clinical criteria and/or conditions | Complete | SR0576-000 | |||
| Cabometyx for Renal Cell Carci... | Cabometyx | Cabozantinib | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | PC0163-000 |
Health Technology Review
Displaying 476 - 500 of 602
Please scroll or swipe to the right to view the full content.
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 476 - 500 of 2138
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| Canagliflozin | Reimbursement Review | Complete | SR0370-000 | ||||
| Linagliptin | Reimbursement Review | Complete | SR0244-000 | ||||
| Linagliptin-metformin | Reimbursement Review | Complete | SR0306-000 | ||||
| Sitagliptin phosphate | Reimbursement Review | Complete | SR0181-000 | ||||
| Sitagliptin phosphate monohydrate / metformin hydrochloride | Reimbursement Review | Complete | SR0182-000 | ||||
| Colorectal cancer | Reimbursement Review | Provisional Funding Algorithm | Withdrawn | PH0043-000 | |||
| Chronic Lymphocytic Leukemia | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0038-000 | |||
| Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Type 2 Diabetes Mellitus, Heart Failure, and Chronic Kidney Disease | This Environmental Scan assesses the current reimbursement of the SGLT2 drug class relevant to public drug programs, including the regulatory, exclusivity, reimbursement review, and reimbursement status of these drugs for type 2 diabetes mellitus, heart failure, and chronic kidney disease. | Horizon Scan | Environmental Scan | Completed | ES0370-000 | ||
| NovoTTF-200A | Health Technology Review | Optimal Use | Completed | OP0554-000 | |||
| Utilization Analysis of Tofacitinib and Other Drugs Among Individuals With Ulcerative Colitis: Feasibility Analysis | Health Technology Review | Observational Study | Complete | OS0003-000 | |||
| Reprocessed Single-Use Semicritical and Critical Medical Devices | We sought to identify and summarize literature evaluating the clinical safety of reprocessed single-used medical devices (SUMDs), defined as infections, mortality, or other adverse events, compared with nonreprocessed (new) SUMDs. | Health Technology Review | Rapid Review | Completed | RC1511-000 | ||
| upadacitinib | Reimbursement Review | Complete | SR0775-000 | ||||
| Aerosol Therapy With Inhalers During Mechanical Ventilation | Health Technology Review | Rapid Review | Completed | RC1529-000 | |||
| Pan- Canadian Rare Disease Registries | Health Technology Review | Environmental Scan | Completed | ES0369-000 | |||
| andexanet alfa | Reimbursement Review | Complete | ST0772-000 | ||||
| Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus | Reimbursement Review | Streamlined Drug Class Review | Complete | TS0002-000 | |||
| Ketamine for Adults With Substance Use Disorders | To inform decisions about using ketamine for treating SUDs, we sought to identify and summarize the literature comparing the clinical and cost-effectiveness of ketamine with placebo or no treatment, with alternative interventions, or among ketamine administered via different routes for SUDs. | Health Technology Review | Rapid Review | Completed | RC1523-000 | ||
| Intra-Articular Hyaluronic Acid for Osteoarthritis of the Hip, Shoulder, and Ankle | Health Technology Review | Rapid Review | Completed | RC1528-000 | |||
| Opioid-Sparing Effects of IV Acetaminophen for Patients Undergoing Surgery | Health Technology Review | Rapid Review | Completed | RC1530-000 | |||
| 2024 Watch List: Care for Children and Youth With Medical Complexity | The 2024 Watch List aims to identify and describe technologies and issues related to the care of children and youth with medical complexity that are likely to affect health care delivery and planning in Canada in the next 5 years. |
Horizon Scan | Roundup | Completed | ER0014-000 | ||
| Photon-Counting CT: High Resolution, Less Radiation | CT scanners play an essential role as medical imaging devices for screening, diagnosis, and monitoring of various health conditions. Photon-counting CT (PCCT) is an emerging medical technology that can improve image quality with less radiation exposure. | Horizon Scan | Emerging Health Technologies | Completed | EH0124-000 | ||
| CADTH Pharmaceutical Reviews Update — Issue 44 | Reimbursement Review | Pharmaceutical Review Update | |||||
| polatuzumab vedotin | Reimbursement Review | Complete | PC0313-000 | ||||
| Cost-Effectiveness of Respiratory Syncytial Virus Vaccines for Adults | Health Technology Review | Technology Review | Completed | HE0047 -000 | |||
| Timing of Antibiotic Therapy for Neisseria Gonorrhoeae Infection | Health Technology Review | Rapid Review | Completed | RC1527-000 |
Provisional Funding Algorithm
Displaying 76 - 81 of 81